Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

Authors:

Abstract
No abstract available
Funding Information
  • Fellowship from the China Postdoctoral Science Foundation
  • Shanghai Sailing Program
  • Program of Shanghai Academic Research Leader
  • Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital Fudan University
  • Shanghai Health Commission Clinical Research Special Project
  • National Science and Technology Major Project of China
  • National Natural Science Foundation of China
  • Key Disease Joint Research Program of Xuhui District

This publication has 23 references indexed in Scilit: